These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 21775098)

  • 21. Dual oral antiplatelet therapy and unplanned surgery: possible role for intravenous platelet glycoprotein receptor inhibitors.
    Bollati M; Giraudi E; Moretti C; Millesimo G; Sciuto F; Omedè P; Biondi Zoccai G; Sheiban I
    J Cardiovasc Med (Hagerstown); 2011 Sep; 12(9):673-4. PubMed ID: 21796059
    [No Abstract]   [Full Text] [Related]  

  • 22. Upstream glycoprotein IIb/IIIa inhibitors for STEMI: use on-time or not at all?
    Seto A; Kern MJ
    Catheter Cardiovasc Interv; 2012 May; 79(6):965-6. PubMed ID: 22511381
    [No Abstract]   [Full Text] [Related]  

  • 23. Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE).
    Tricoci P; Peterson ED; Chen AY; Newby LK; Harrington RA; Greenbaum AB; Cannon CP; Gibson CM; Hoekstra JW; Pollack CV; Ohman EM; Gibler WB; Roe MT
    Am J Cardiol; 2007 May; 99(10):1389-93. PubMed ID: 17493466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of upstream antiplatelet therapy use before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the CRUSADE National Quality Improvement Initiative).
    Alexander D; Mann N; Ou FS; Peterson ED; Ohman EM; Gibler WB; Roe MT
    Am J Cardiol; 2008 Nov; 102(10):1335-40. PubMed ID: 18993151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gastrointestinal bleeding and outcomes after percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Chua SK; Liao CS; Hung HF; Cheng JJ; Chiu CZ; Chang CM; Lee SH; Lin SC; Liou JY; Lo HM; Kuan P; Shyu KG
    Am J Crit Care; 2011 May; 20(3):218-25. PubMed ID: 21532042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Platelet aggregation upon acetylsalicylic acid and clopidogrel treatment and glycoprotein IIb/IIIa content in patients with acute coronary syndrome].
    Khaspekova SG; Ziuriaev IT; Iakushkin VV; Golubeva NV; Ruda MIa; Mazurov AV
    Kardiologiia; 2011; 51(7):4-7. PubMed ID: 21878077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [New antiaggregants and their importance for the practitioner].
    Tsakiris DA
    Ther Umsch; 2003 Jan; 60(1):24-6. PubMed ID: 12638474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years?
    Silva MA; Gandhi PJ
    J Clin Pharm Ther; 2004 Dec; 29(6):497-510. PubMed ID: 15584937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials.
    Lin GM; Han CL
    Eur Heart J; 2010 Mar; 31(6):753-4. PubMed ID: 20093259
    [No Abstract]   [Full Text] [Related]  

  • 30. [Glycoprotein IIb-IIIa antagonist Monafram in primary angioplasty of patients with acute coronary syndrome without st segment elevation].
    Pevzner DV; Staroverov II; Samko AN; Frolova NS; Mazurov AV; Ruda MY
    Kardiologiia; 2010; 50(6):22-6. PubMed ID: 20659023
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Shen J; Zhang Q; Zhang RY; Zhang JS; Hu J; Yang ZK; Zheng AF; Zhang X; Shen WF
    Coron Artery Dis; 2008 Jun; 19(4):271-7. PubMed ID: 18480672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial.
    Wang TY; White JA; Tricoci P; Giugliano RP; Zeymer U; Harrington RA; Montalescot G; James SK; Van de Werf F; Armstrong PW; Braunwald E; Califf RM; Newby LK
    Circulation; 2011 Feb; 123(7):722-30. PubMed ID: 21300952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Higher efficacy of pre-hospital tirofiban with longer pre-treatment time to primary PCI: protection for the negative impact of time delay.
    Heestermans T; de Boer MJ; van Werkum JW; Mosterd A; Gosselink AT; Dambrink JH; van Houwelingen G; Koopmans P; Hamm C; Zijlstra F; ten Berg JM; van 't Hof AW
    EuroIntervention; 2011 Aug; 7(4):442-8. PubMed ID: 21764662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomised controlled trial evaluating the role of tirofiban in high-risk non-ST elevation acute coronary syndromes: an East Indian perspective.
    Bhattacharya R; Pani A; Dutta D; Basak S; Gangopadhyay S; Das Baksi S; Sarkar RN
    Singapore Med J; 2010 Jul; 51(7):558-64. PubMed ID: 20730395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score.
    Hermanides RS; Ottervanger JP; ten Berg JM; Gosselink AT; van Houwelingen G; Dambrink JH; Stella PR; Hamm C; van 't Hof AW;
    J Invasive Cardiol; 2012 Mar; 24(3):84-9. PubMed ID: 22388296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
    Cannon CP; Weintraub WS; Demopoulos LA; Vicari R; Frey MJ; Lakkis N; Neumann FJ; Robertson DH; DeLucca PT; DiBattiste PM; Gibson CM; Braunwald E;
    N Engl J Med; 2001 Jun; 344(25):1879-87. PubMed ID: 11419424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Experience of treatment of patients with myocardial infarction without raise of ST segment on ECG of high risk of cardiocomplications by method of coronary angioplasty].
    Shames AB; Igonin VA; Krashutskiĭ VV; Ivanov VA; Terekhin SA
    Voen Med Zh; 2010 Jan; 331(1):35-9. PubMed ID: 20536036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of platelet surface receptors and early changes in platelet function in patients with STEMI treated with abciximab and clopidogrel versus clopidogrel alone.
    Konopka A; Spychalska J; Sitkiewicz D; Zdebska E; Pilichowska I; Piotrowski W; Stepińska J
    Am J Cardiovasc Drugs; 2007; 7(6):433-9. PubMed ID: 18076210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction.
    Heestermans AA; Van Werkum JW; Hamm C; Dill T; Gosselink AT; De Boer MJ; Van Houwelingen G; Hoorntje JC; Koopmans PC; Ten Berg JM; Van 't Hof AW
    J Thromb Haemost; 2009 Oct; 7(10):1612-8. PubMed ID: 19682233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Challenges in oral antiplatelet therapy: ST-segment elevation myocardial infarction.
    Dauerman HL
    Am J Cardiol; 2009 Sep; 104(5 Suppl):39C-43C. PubMed ID: 19695360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.